9p21 deletion correlates with recurrence in head and neck cancer

Head and Neck

Volumn 20, Issue 2, 1998, Pages 113-118

  Lydiatt, William M ^a   Davidson, Bruce J ^b   Schantz, Stimson P ^c   Caruana, Salvatore ^c   Chaganti, Raju S K ^c  

^a Methodist Hospital Omaha   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

9p21; Head and neck cancer; IFN; Loss of heterozygosity; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; PROTEIN P16;

ADULT; ARTICLE; CARCINOGENESIS; CHROMOSOME 9P; CHROMOSOME DELETION; CHROMOSOME MAP; CLINICAL ARTICLE; FEMALE; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; TUMOR SUPPRESSOR GENE;

AGED; BLOTTING, SOUTHERN; CARCINOMA, SQUAMOUS CELL; CENTROMERE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; GENES, P16; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-BETA; INTERFERONS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TELOMERE;

EID: 0031931231     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0347(199803)20:2<113::AID-HED3>3.0.CO;2-5     Document Type: Article

References (34)

1. Lydiatt WM, Davidson BJ, Shah J, Schantz SP, Chaganti RSK. The relationship of loss of heterozygosity to tobacco exposure and early recurrence in head and neck squamous cell carcinoma. Am J Surg 1994;168:437-440.
2. Nawroz H, van der Reit P, Hruban RH, Koch W, Ruppert M, Sidransky D. Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994;54:1152-1155.
3. Ah-See KW, Cooke TG, Pickford IR, Soutar D, Balmain A. An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res 1994;54: 1617-1621.
4. Li X, Lee NK, Ye Y-W, et al. Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 1994;86: 1524-1529.
5. van der Reit P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994;54:1156-1158.
6. Merlo A, Gabrielson E, Askin F, Sidransky D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 1994;54:640-642.
7. Cheng JQ, Jhanwar SC, Lu YY, Testa JR. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 1993;53:4761-4763.
8. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989;244:207-211.
9. Rowley JD, Aster JC, Sklar J. The clinical applications of new DNA diagnostic technology on the management of cancer patients. JAMA 1993;270:2331-2337.
10. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
11. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
12. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368: 753-756.
13. Marx J. A challenge to p16 gene as a major tumor suppressor. Science 1994;264:1846.
14. Lydiatt WM, Murty VVVS, Davidson BJ, et al. Homozygous deletions and loss of expression of the CDKN2 gene occurs frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes Chromosom Cancer 1995;13:94-98.
15. Zhang S-Y, Klein-Szanto JP, Sauter ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994;54:5050-5053.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual, second ed. New York: Cold Spring Harbor Laboratory Press, 1989.
17. Southern E. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975;98:503-507.
18. Murty VVVS, Houldsworth J, Baldwin S, et al. Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. Proc Natl Acad Sci USA 1992;89:11006-11010.
19. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988;80:1159-1164.
20. Heyman M, Grander D, Brondum-Nielsen K, Liu Y, Soderhall S, Einhorn S. Deletions of the short arm of chromosome 9, including the interferon-α/-β genes, in acute lymphocytic leukemia. Studies on loss of heterozygosity, parental origin of deleted genes and prognosis. Int J Cancer 1993;54:748-753.
21. Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE, Cordon-Cardo C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res 1994;54:2848-2851.
22. Olopade OI, Pomykala HM, Hagos F, et al. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci USA 1995;92:6489-6493.
23. INK4a tumor suppressor protein. Cancer Res 1995;55:2503-2506.
24. INK4 gene mediated by an adenovirus vector. Cancer Res 1995;55:3250-3253.
25. Merlo A, Herman JG, Mao L, et al. 5′ CpG Island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Natl Med 1995;1:686-692.
26. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nature Genet 1994;8:15-21.
27. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994;8: 22-26.
28. Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55: 2713-2718.
29. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 Alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547-5551.
30. Kamb A, Liu Q, Harshman K, Tavtigian S. Letter of response. Science 1994;265:416-417.
31. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265:415-416.
32. Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ, Coto E. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res 1995;1:1043-1049.
33. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genetics 1995;11:210-212.
34. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56: 3630-3633.